REVA Completes Clinical Enrollment Milestone
SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) is pleased to announce that it has enrolled the first cohort of 110 patients in the FANTOM II clinical trial. Achievement of this milestone is key to the Company’s planned CE Mark application of its Fantom® sirolimus-eluting bioresorbable scaffold. The CE Mark application, planned for mid-2016, will be based upon data from these patients through the six-month time point. The Fantom scaffold, made from REVA’s advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from